MX2023001217A - Metodos de tratamiento de linfomas mutantes. - Google Patents

Metodos de tratamiento de linfomas mutantes.

Info

Publication number
MX2023001217A
MX2023001217A MX2023001217A MX2023001217A MX2023001217A MX 2023001217 A MX2023001217 A MX 2023001217A MX 2023001217 A MX2023001217 A MX 2023001217A MX 2023001217 A MX2023001217 A MX 2023001217A MX 2023001217 A MX2023001217 A MX 2023001217A
Authority
MX
Mexico
Prior art keywords
methods
lymphomas
mutant
treating
treating mutant
Prior art date
Application number
MX2023001217A
Other languages
English (en)
Inventor
Duncan Walker
Original Assignee
Kymera Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kymera Therapeutics Inc filed Critical Kymera Therapeutics Inc
Publication of MX2023001217A publication Critical patent/MX2023001217A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a métodos para tratar linfomas de células B mutantes en MYD88 usando degradadores de IRAK4.
MX2023001217A 2020-07-30 2021-07-29 Metodos de tratamiento de linfomas mutantes. MX2023001217A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063058891P 2020-07-30 2020-07-30
US202063109854P 2020-11-04 2020-11-04
US202163202242P 2021-06-02 2021-06-02
PCT/US2021/071048 WO2022027058A1 (en) 2020-07-30 2021-07-29 Methods of treating mutant lymphomas

Publications (1)

Publication Number Publication Date
MX2023001217A true MX2023001217A (es) 2023-03-03

Family

ID=80036177

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023001217A MX2023001217A (es) 2020-07-30 2021-07-29 Metodos de tratamiento de linfomas mutantes.

Country Status (12)

Country Link
US (1) US11857535B2 (es)
EP (1) EP4188374A1 (es)
JP (1) JP2023536462A (es)
KR (1) KR20230044480A (es)
CN (1) CN116133692A (es)
AU (1) AU2021316053A1 (es)
BR (1) BR112023001638A2 (es)
CA (1) CA3187255A1 (es)
IL (1) IL300175A (es)
MX (1) MX2023001217A (es)
TW (1) TW202220653A (es)
WO (1) WO2022027058A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024073507A1 (en) 2022-09-28 2024-04-04 Theseus Pharmaceuticals, Inc. Macrocyclic compounds and uses thereof
CN115572768B (zh) * 2022-11-04 2023-12-19 山东第一医科大学附属省立医院(山东省立医院) 一种针对弥漫大b细胞淋巴瘤的预后评估及联合治疗

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200509718B (en) 2003-05-30 2007-03-28 Gemin X Biotechnologies Inc Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
DK2343320T3 (da) 2005-03-25 2018-01-29 Gitr Inc Anti-gitr-antistoffer og anvendelser deraf
AU2006297853B2 (en) 2005-05-12 2010-08-19 AbbVie Global Enterprises Ltd. Apoptosis promoters
SI1907424T1 (sl) 2005-07-01 2015-12-31 E. R. Squibb & Sons, L.L.C. Humana monoklonska protitelesa proti programiranem smrtnem ligandu 1 (PD-L1)
US8394794B2 (en) 2007-03-23 2013-03-12 Regents Of The University Of Minnesota Therapeutic compounds
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
EP2175884B8 (en) 2007-07-12 2017-02-22 GITR, Inc. Combination therapies employing gitr binding molecules
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
WO2009073620A2 (en) 2007-11-30 2009-06-11 Newlink Genetics Ido inhibitors
US8748469B2 (en) 2008-04-24 2014-06-10 Newlink Genetics Corporation IDO inhibitors
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
CN108997498A (zh) 2008-12-09 2018-12-14 霍夫曼-拉罗奇有限公司 抗-pd-l1抗体及它们用于增强t细胞功能的用途
US8921037B2 (en) 2008-12-16 2014-12-30 Bo Han PF4-depleted platelet rich plasma preparations and methods for hard and soft tissue repair
LT3023438T (lt) 2009-09-03 2020-05-11 Merck Sharp & Dohme Corp. Anti-gitr antikūnai
US8722720B2 (en) 2009-10-28 2014-05-13 Newlink Genetics Corporation Imidazole derivatives as IDO inhibitors
MY159679A (en) 2009-12-10 2017-01-13 Hoffmann La Roche Antibodies binding preferentially human csf1r extracellular domain 4 and their use
NZ602161A (en) 2010-03-04 2014-12-24 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
MX2012010014A (es) 2010-03-05 2012-09-21 Hoffmann La Roche Anticuerpos contra csf-1r humano y sus usos.
KR101647871B1 (ko) 2010-03-05 2016-08-11 에프. 호프만-라 로슈 아게 인간 ｃｓｆ-1ｒ에 대한 항체 및 이의 용도
TR201900368T4 (tr) 2010-05-04 2019-02-21 Five Prime Therapeutics Inc Csf1r'ye bağlanan antikorlar.
RU2710717C2 (ru) 2010-09-09 2020-01-10 Пфайзер Инк. Молекулы, связывающиеся с 4-1ВВ
NO2694640T3 (es) 2011-04-15 2018-03-17
LT2699264T (lt) 2011-04-20 2018-07-10 Medimmune, Llc Antikūnai ir kitos molekulės, kurios jungiasi prie b7-h1 ir pd-1
KR101981873B1 (ko) 2011-11-28 2019-05-23 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
CN104159921B (zh) 2011-12-15 2018-05-04 霍夫曼-拉罗奇有限公司 针对人csf-1r的抗体及其用途
MX2014008961A (es) 2012-02-06 2014-10-14 Genentech Inc Composiciones y metodos para utilizar inhibidores de csf1r.
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
CA2871445C (en) 2012-05-11 2020-07-07 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
CN107759690A (zh) 2012-08-31 2018-03-06 戊瑞治疗有限公司 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
WO2019099926A1 (en) 2017-11-17 2019-05-23 Arvinas, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
JP2021508703A (ja) 2017-12-26 2021-03-11 カイメラ セラピューティクス， インコーポレイテッド Ｉｒａｋ分解剤およびそれらの使用
AU2019220632B2 (en) * 2018-02-14 2024-02-22 Dana-Farber Cancer Institute, Inc. IRAK degraders and uses thereof
WO2020010227A1 (en) 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Protein degraders and uses thereof
AU2019371400A1 (en) 2018-11-02 2021-04-08 Dana-Farber Cancer Institute, Inc. Acetylation writer inhibitor development and uses thereof
CA3119773A1 (en) 2018-11-30 2020-06-04 Kymera Therapeutics, Inc. Irak degraders and uses thereof
WO2020264499A1 (en) 2019-06-28 2020-12-30 Kymera Therapeutics, Inc. Irak degraders and uses thereof
US11779578B2 (en) 2019-12-17 2023-10-10 Kymera Therapeutics, Inc. IRAK degraders and uses thereof

Also Published As

Publication number Publication date
BR112023001638A2 (pt) 2023-02-23
US11857535B2 (en) 2024-01-02
CN116133692A (zh) 2023-05-16
US20220054453A1 (en) 2022-02-24
KR20230044480A (ko) 2023-04-04
AU2021316053A1 (en) 2023-03-02
WO2022027058A1 (en) 2022-02-03
EP4188374A1 (en) 2023-06-07
JP2023536462A (ja) 2023-08-25
IL300175A (en) 2023-03-01
TW202220653A (zh) 2022-06-01
CA3187255A1 (en) 2022-02-03

Similar Documents

Publication Publication Date Title
MX2023011282A (es) Analogos de rapamicina ligados a c40, c28 y c-32 como inhibidores de mtor.
MX2023001217A (es) Metodos de tratamiento de linfomas mutantes.
MX2020011564A (es) Analogos de rapamicina unidos a c26 como inhibidores de mtor.
MX2023005160A (es) Compuestos de 4-aminoisoindolina-1,3-diona sustituidos y su uso para el tratamiento de linfoma.
PH12019502138A1 (en) Compounds and compositions for treating hematological disorders
MX2020001757A (es) Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
MX2021016049A (es) Metodos de uso de inhibidores de rad51 para el tratamiento de cancer de pancreas.
CR20200088A (es) Compuestos espirocíclicos y sus métodos de preparación y uso
MX2023010429A (es) Inhibidores del homologo del oncogen viral del sarcoma de rata kirsten (kras).
PH12017502123A1 (en) Substituted benzamides and methods of use thereof
PH12020500372A1 (en) Spirocycle compounds and methods of making and using same
MX2022001004A (es) Inhibidores de enzimas.
MX2021001565A (es) Inhibidores tipo indol y azaindol de enzimas peptidil arginina deiminasas (pad).
MX2022003904A (es) Proceso para reducir los malos olores en telas.
MX2023001296A (es) Composiciones y metodos para tratar enfermedades y trastornos.
MX2022000743A (es) Tratamiento mejorado utilizando eyp001.
MX2023013173A (es) Degradadores de cinasa 2 dependiente de ciclina (cdk2) y sus usos.
MX2022000811A (es) Inhibidores de enzimas.
MX2022002069A (es) Inhibidores de enzimas.
MX2023006719A (es) Degradadores de cinasas asociadas con el receptor de interleucina 1 (irak) y sus usos.
MX2022004270A (es) Inhibidores de aldosa reductasa para el tratamiento de la deficiencia de fosfomannomutasa 2.
MX2022000742A (es) Metodo para disminuir los efectos adversos del interferon.
IL279168B (en) A process for the preparation of eribulin
MX2022002446A (es) Compuestos de pirrolopirimidina inhibidores de perk.
MX2020012990A (es) Formulaciones de tegavivint y compuestos relacionados.